Skip to content

G&A at other companies

Janux Therapeutics logo
Janux TherapeuticsJANX
$11.13M+13.1%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$26.2M+85.4%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$23.82M+25.1%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$21.95M+31.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$6.85M+23.6%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$5.71M-5.2%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's G&A?
Xencor (XNCR) reported G&A of $17.71M in Q1 2026.
How has Xencor's G&A changed year-over-year?
Xencor's G&A increased by 2.1% year-over-year, from $17.34M to $17.71M.
What is the long-term trend for Xencor's G&A?
Over 4 years (2021 to 2025), Xencor's G&A has grown at a 13.1% compound annual growth rate (CAGR), from $38.84M to $63.64M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.